| Ticker | HALO |
|---|---|
| ISIN | US40637H1095 |
| Sector | Atención sanitaria |
| Mercado | NASDAQ |
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex reco...
Halozyme Therapeutics, Inc. opera en el sector Healthcare, industria Biotechnology.